SCOTUS Mifepristone Dissent Hints at Next Phase of Abortion Rights Fight

Key Points:

• The Supreme Court ruled that telehealth access to the abortion drug mifepristone can continue, with Justices Clarence Thomas and Samuel Alito dissenting and signaling future conflicts over abortion rights.
• Thomas cited the 1873 Comstock Act, which bans mailing abortion drugs, as a basis to restrict access, despite legal arguments that the law is unenforceable and a 2022 DOJ memo clarifying it does not apply to abortion medication.
• The FDA began a politically charged safety review of mifepristone in late 2025, raising concerns among advocates about potential restrictions, especially after the appointment of FDA Commissioner Kyle Diamantas, who expressed anti-abortion views.
• The ruling maintains telehealth and mail access to mifepristone while the Louisiana v. FDA case proceeds, countering a recent 5th Circuit decision that had reinstated in-person dispensing requirements.
• Advocates warn that despite this temporary victory, threats to abortion access remain significant, with anti-abortion forces poised to use laws like the Comstock Act and political timing around elections to further restrict medication abortion.